- Topical Steroids
- Anti-viral drugs
- Interferons
- Others
Herpetic Keratitis Market was valued at USD 4,130 Million in 2022 and is poised to grow at a CAGR of 6.1% over 2023-2029. Herpetic keratitis is a form of keratitis caused by recurrent herpes simplex virus infection in the cornea, which begins with infection of the epithelial cells on the surface of the eye and retrograde infection of nerves serving the cornea and is characterized by swelling of the conjunctiva and eyelids. Based on the treatment type, the anti-viral segment is anticipated to dominate the herpetic keratitis market share over the forecast period. According to the World Health Organization, nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection, and around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. The increasing prevalence of chronic diseases, rapid advancements in the healthcare sector, and high adoption of techniques are the major herpetic keratitis market growth drivers, while the high cost of treatment could hinder the growth of the market. The increasing rate of mergers and acquisitions will act as an opportunity for geographical expansion of the market.
Herpetic Keratitis Market key Developments:
- In April 2019, Fera Pharmaceuticals’s Avaclyr was approved by the US FDA for the treatment of acute herpetic keratitis in patients.
- In Sep 2021, Aurobindo Pharma received an Indian patent for Valacyclovir, an anti-viral drug from the Indian patent office.
Herpetic Keratitis Market Summary
Study Period
2023-29
Base Year
2022
CAGR
6.1%
Largest Market
North America
Fastest Growing Market
North America
Herpetic Keratitis Market Dynamics
The rising focus on drug development, increasing demand for precision medicine, high adoption of home care settings, point-of-care diagnostics, and increasing investments in research and development activities are expected to drive the market revenue growth during the forecast period. For instance, in 2019 a randomized trial was conducted using topical corticosteroid in addition to oral antivirals for HSV keratitis recurrence prevention. Moreover, approved drugs such as Famciclovir, Valacyclovir, Acyclovir, and other drugs are being used in the treatment of HSV infection. However, the challenges associated with the diagnosis of the disease could act as a restraining factor.
North-America Got Significant Share of
Herpetic Keratitis Market Regional Analysis
The Herpetic Keratitis market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the American Academy of Ophthalmology, as of 2020, the global prevalence of HSV keratitis was estimated at 1.5 million yearly, and in the USA, approximately 5,00,000 diagnosed people have ocular HSV. The North American herpetic Keratitis market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and the rising prevalence and incidences of infectious diseases in the region. The Asia Pacific market is also expected to witness significant growth owing to the presence of generic manufacturers, and an increasing patient population in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Herpetic Keratitis Market Segmentation
By Treatment
By Disease Type
- Epithelial
- Disciform
- Neurotrophic
- Necrotizing
By Route of Administration
- Oral
- Topical
By End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Frequently Asked Questions
The Herpetic Keratitis market was valued at USD 4,130 million in 2022 and is expected to grow at a 6.1% CAGR over the forecast period 2023 – 2029.
The increasing rate of mergers and acquisitions is the key opportunity for the Herpetic Keratitis market.
The increasing prevalence of skin conditions, rapid advancements in the healthcare sector, and high adoption of techniques are the growth drivers in the Herpetic Keratitis market.
Bausch & Lomb Incorporated, Vectans Pharma, GlaxoSmithKline plc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Jubilant Cadista, Mylan N.V., and Blistex are a few companies operating in the Herpetic Keratitis market.
- Bausch & Lomb Incorporated
- Vectans Pharma
- GlaxoSmithKline plc.
- Aurobindo Pharma Ltd.
- Reddy's Laboratories Ltd.
- Cipla Ltd.
- Jubilant Cadista
- Mylan N.V.
- Blistex